Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia

Y. C. Huang, H. T. Kao, T. Y. Lin, A. J. Kuo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The objective of this article is to assess the distribution of minimal inhibition concentrations (MIC) for candidal isolates from bloodstreams in neonates and to assess the correlation of clinical outcome with antifungal susceptibility testing. Of the 62 episodes of neonatal candidemia in a Children's Hospital between January 1994 and July 1998, 38 stocked isolates from 38 infants' bloodstreams were available and underwent antifungal susceptibility test according to National Committee for Clinical Laboratory Standards M27-A document. Correlation of clinical response with in vitro results was assessed in 37 patient-episode-isolate events. No less than 90% of these isolates tested were susceptible to amphotericin B, flucytosin, and fluconazole. The ranges of amphotericin B MICs and flucytosin MICs were narrow, ranging from 0.25 to 2 μg/mL, respectively. The range of fluconazole MICs was broad, ranging from 0.25 to >64 μg/mL. Successful therapy was achieved in 18 (62%) of 29 amphotericin B-treated patient-episode-susceptible isolate (MIC ≤1 μg/mL) events and 9 (64%) of 14 fluconazole-treated patient-episode-susceptible isolate events, respectively. Most isolates from the bloodstreams of neonates with candidemia were susceptible to antifungal agents tested but a low MIC of the antifungal agent did not predict successful therapy in this study. Correlating MICs with clinical outcome in neonatal candidemia requires complex evaluation of other factors.

Original languageEnglish
Pages (from-to)141-146
Number of pages6
JournalAmerican Journal of Perinatology
Volume18
Issue number3
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Candidemia
Fluconazole
Amphotericin B
Antifungal Agents
Newborn Infant
Therapeutics

Keywords

  • Antifungal susceptibility test
  • Candidemia
  • Neonate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynaecology

Cite this

Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. / Huang, Y. C.; Kao, H. T.; Lin, T. Y.; Kuo, A. J.

In: American Journal of Perinatology, Vol. 18, No. 3, 2001, p. 141-146.

Research output: Contribution to journalArticle

@article{9b6b174f3a044ff4ac8602be844ae201,
title = "Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia",
abstract = "The objective of this article is to assess the distribution of minimal inhibition concentrations (MIC) for candidal isolates from bloodstreams in neonates and to assess the correlation of clinical outcome with antifungal susceptibility testing. Of the 62 episodes of neonatal candidemia in a Children's Hospital between January 1994 and July 1998, 38 stocked isolates from 38 infants' bloodstreams were available and underwent antifungal susceptibility test according to National Committee for Clinical Laboratory Standards M27-A document. Correlation of clinical response with in vitro results was assessed in 37 patient-episode-isolate events. No less than 90{\%} of these isolates tested were susceptible to amphotericin B, flucytosin, and fluconazole. The ranges of amphotericin B MICs and flucytosin MICs were narrow, ranging from 0.25 to 2 μg/mL, respectively. The range of fluconazole MICs was broad, ranging from 0.25 to >64 μg/mL. Successful therapy was achieved in 18 (62{\%}) of 29 amphotericin B-treated patient-episode-susceptible isolate (MIC ≤1 μg/mL) events and 9 (64{\%}) of 14 fluconazole-treated patient-episode-susceptible isolate events, respectively. Most isolates from the bloodstreams of neonates with candidemia were susceptible to antifungal agents tested but a low MIC of the antifungal agent did not predict successful therapy in this study. Correlating MICs with clinical outcome in neonatal candidemia requires complex evaluation of other factors.",
keywords = "Antifungal susceptibility test, Candidemia, Neonate",
author = "Huang, {Y. C.} and Kao, {H. T.} and Lin, {T. Y.} and Kuo, {A. J.}",
year = "2001",
doi = "10.1055/s-2001-14524",
language = "English",
volume = "18",
pages = "141--146",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia

AU - Huang, Y. C.

AU - Kao, H. T.

AU - Lin, T. Y.

AU - Kuo, A. J.

PY - 2001

Y1 - 2001

N2 - The objective of this article is to assess the distribution of minimal inhibition concentrations (MIC) for candidal isolates from bloodstreams in neonates and to assess the correlation of clinical outcome with antifungal susceptibility testing. Of the 62 episodes of neonatal candidemia in a Children's Hospital between January 1994 and July 1998, 38 stocked isolates from 38 infants' bloodstreams were available and underwent antifungal susceptibility test according to National Committee for Clinical Laboratory Standards M27-A document. Correlation of clinical response with in vitro results was assessed in 37 patient-episode-isolate events. No less than 90% of these isolates tested were susceptible to amphotericin B, flucytosin, and fluconazole. The ranges of amphotericin B MICs and flucytosin MICs were narrow, ranging from 0.25 to 2 μg/mL, respectively. The range of fluconazole MICs was broad, ranging from 0.25 to >64 μg/mL. Successful therapy was achieved in 18 (62%) of 29 amphotericin B-treated patient-episode-susceptible isolate (MIC ≤1 μg/mL) events and 9 (64%) of 14 fluconazole-treated patient-episode-susceptible isolate events, respectively. Most isolates from the bloodstreams of neonates with candidemia were susceptible to antifungal agents tested but a low MIC of the antifungal agent did not predict successful therapy in this study. Correlating MICs with clinical outcome in neonatal candidemia requires complex evaluation of other factors.

AB - The objective of this article is to assess the distribution of minimal inhibition concentrations (MIC) for candidal isolates from bloodstreams in neonates and to assess the correlation of clinical outcome with antifungal susceptibility testing. Of the 62 episodes of neonatal candidemia in a Children's Hospital between January 1994 and July 1998, 38 stocked isolates from 38 infants' bloodstreams were available and underwent antifungal susceptibility test according to National Committee for Clinical Laboratory Standards M27-A document. Correlation of clinical response with in vitro results was assessed in 37 patient-episode-isolate events. No less than 90% of these isolates tested were susceptible to amphotericin B, flucytosin, and fluconazole. The ranges of amphotericin B MICs and flucytosin MICs were narrow, ranging from 0.25 to 2 μg/mL, respectively. The range of fluconazole MICs was broad, ranging from 0.25 to >64 μg/mL. Successful therapy was achieved in 18 (62%) of 29 amphotericin B-treated patient-episode-susceptible isolate (MIC ≤1 μg/mL) events and 9 (64%) of 14 fluconazole-treated patient-episode-susceptible isolate events, respectively. Most isolates from the bloodstreams of neonates with candidemia were susceptible to antifungal agents tested but a low MIC of the antifungal agent did not predict successful therapy in this study. Correlating MICs with clinical outcome in neonatal candidemia requires complex evaluation of other factors.

KW - Antifungal susceptibility test

KW - Candidemia

KW - Neonate

UR - http://www.scopus.com/inward/record.url?scp=0034952461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034952461&partnerID=8YFLogxK

U2 - 10.1055/s-2001-14524

DO - 10.1055/s-2001-14524

M3 - Article

VL - 18

SP - 141

EP - 146

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 3

ER -